Ptc Therapeutics (PTCT) Non Operating Income (2012 - 2026)

Ptc Therapeutics' Non Operating Income history runs 15 years deep, the most recent figure standing at -$49.0 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 43.82% year-over-year to -$49.0 million in Q1 2026; TTM through Mar 2026 was -$167.2 million, a 4.32% decrease from a year earlier, with the FY2025 full-year figure at -$152.2 million, up 8.84% from the prior year.
• Non Operating Income improved to -$49.0 million in Q1 2026 per PTCT's latest filing, from -$55.2 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$20.9 million in Q3 2022 and bottomed at -$55.2 million in Q4 2025.
• The 5-year median for Non Operating Income is -$32.6 million (2025), against an average of -$34.6 million.
• Across the five-year window, Non Operating Income sank 80.71% in 2023 and soared 30.2% in 2025, its largest moves.
• Year by year, Non Operating Income stood at -$24.5 million in 2022, then sank by 80.71% to -$44.3 million in 2023, then advanced by 7.26% to -$41.1 million in 2024, then tumbled by 34.41% to -$55.2 million in 2025, then climbed by 11.16% to -$49.0 million in 2026.
• Per Business Quant, the three latest PTCT Non Operating Income figures stand at -$49.0 million (Q1 2026), -$55.2 million (Q4 2025), and -$32.6 million (Q3 2025).